Clincosm LogoSign in Get a demo

Clinical Trial of Quantitative Detection Kit for Hsp90α in Hepatic Cancer

Sponsor
Protgen Ltd (Industry)
Overall Status
Unknown status
CT.gov ID
NCT02324127
Collaborator
(none)
1,100
Enrollment
1
Location
1
Arm
26
Duration (Months)
42.3
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Detect plasma Hsp90α concentration of liver cancer patients, healthy volunteers, benign liver diseases.

Condition or Disease Intervention/Treatment Phase
  • Device: hsp90
 N/A

Detailed Description

Detect plasma Hsp90α concentration of liver cancer patients, healthy volunteers, benign liver diseases, validate accuracy, specificity and sensitivity of Hsp90α kit.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
1100 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Clinical Trial of Quantitative Detection Kit for Hsp90α in Hepatic Cancer
Study Start Date :
Oct 1, 2012
Anticipated Primary Completion Date :
Dec 1, 2014
Anticipated Study Completion Date :
Dec 1, 2014

Arms and Interventions

Arm Intervention/Treatment
Experimental: liver cancer

Detect plasma Hsp90α concentration of liver cancer patients

Device: hsp90
Detect plasma Hsp90α concentration of lung cancer patients
Other Names:
  • biomarker

    		•

    Outcome Measures

    Primary Outcome Measures

    1. Hsp90α Concentration of plasma [4 months]

      Detect Hsp90α Concentration(ng/ml) of plasma and calculate the accuracy, specificity and sensitivity of Hsp90α kit

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:

    • Liver cancer patients

    • Healthy volunteers,

    • Benign liver diseases patients

    Exclusion Criteria:
    • Patients who Previously accepted radiotherapy

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Zhejiang Medical University Cancer Institute and Hospital Hangzhou Zhejiang China

    Sponsors and Collaborators

    • Protgen Ltd

    Investigators

    • Principal Investigator: Shusen Zhen, MD, The first hospital of Zhejiang province

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Protgen Ltd
    ClinicalTrials.gov Identifier:
    NCT02324127
    Other Study ID Numbers:
    • hsp90a2011-05
    First Posted:
    Dec 24, 2014
    Last Update Posted:
    Dec 24, 2014
    Last Verified:
    Dec 1, 2014
    Additional relevant MeSH terms:
    Liver Neoplasms

    Study Results

    No Results Posted as of Dec 24, 2014